A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Short-Acting β(1)-Adrenergic Receptor Blocker Landiolol Hydrochloride for Coronary Computed Tomography Angiography in Japanese Patients with Suspected Ischemic Cardiac Disease

Similar Items

• A Multicenter, Open-Label Study of an Intravenous Short-Acting β(1)-Adrenergic Receptor Antagonist Landiolol Hydrochloride for Coronary Computed Tomography Angiography by 16-Slice Multi-Detector Computed Tomography in Japanese Patients with Suspected Ischemic Cardiac Disease
  od: Hirano, Masaharu, i dr.
  Izdano: (2014)
• A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β(1)-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease
  od: Jinzaki, Masahiro, i dr.
  Izdano: (2013)
• Dose-Finding Study of Landiolol Hydrochloride: A Short-Acting β(1)-Blocker for Controlling Heart Rate During Coronary Computed-Tomography Angiography in Japan
  od: Hirano, Masaharu, i dr.
  Izdano: (2013)
• A case of ultrashort‐acting beta‐blocker landiolol hydrochloride for takotsubo syndrome with left ventricular outflow tract obstruction
  od: Takama, Takuro, i dr.
  Izdano: (2018)
• Perioperative Administration of an Intravenous Beta-Blocker Landiolol Hydrochloride in Patients with Lung Cancer: A Japanese Retrospective Exploratory Clinical Study
  od: Sakamoto, Atsuhiro, i dr.
  Izdano: (2019)